AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones
More than a year after AstraZeneca $AZN grabbed two of Ionis’ $IONS antisense drug candidates in back-to-back deals, the pharma giant has come back with a $330 million licensing agreement for a fresh product candidate now headed into the clinic.
The UK pharma giant is paying $30 million upfront to develop and commercialize IONIS-AZ5-2.5Rx, or AZD2373. The antisense drug will treat a genetically associated form of kidney disease, the partners noted, but they are keeping the exact target to themselves for now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
